OpRegen® | Hadassah International

Safety Success in Hadassah AMD Stem Cell Trial to be Presented at International Conference

Data from the first patient cohort of the Phase I/IIa Hadassah Medical Organization clinical trial with the stem cell product, OpRegen®, aimed at slowing the progression of the advanced form…

Facebook

Twitter

Macular Degeneration

Successful Start to Hadassah’s Unique Stem Cell Clinical Trial to Treat Major Cause of Blindness

Macular Degeneration

Clinical Trial of Hadassah-Developed Stem Cell Treatment for Macular Degeneration Gets Go-Ahead from FDA

Macular Degeneration

Hadassah International

Safety Success in Hadassah AMD Stem Cell Trial to be Presented at International Conference

Safety Success in Hadassah AMD Stem Cell Trial to be Presented at International Conference

Successful Start to Hadassah’s Unique Stem Cell Clinical Trial to Treat Major Cause of Blindness

Hadassah University Hospital is currently recruiting patients with the retinal disease

Clinical Trial of Hadassah-Developed Stem Cell Treatment for Macular Degeneration Gets Go-Ahead from FDA

Hadassah-Generated Stem Cell Treatment for Macular Degeneration to be Developed and Commercialized